Name | Title | Contact Details |
---|
Save time, money and resources with the smarter, simpler, and safer way to handle regulated medical waste
All-american Allergy Alternatives is a Appleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in China, Egypt, India and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East.
A brand new 503B outsourcing facility.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite`s strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite`s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product.